Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-α polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients

Tarragô, Andréa Monteiro; Costa, Allyson Guimarães; Pimentel, João Paulo Diniz; Gomes, Samara Tatielle Monteiro; Freitas, Felipe Bonfim; Lalwani, Pritesh; Araújo, Ana Ruth; Victoria, Flamir da Silva; Victoria, Marilu Barbieri; Vallinoto, Antônio Carlos Rosário; Sadahiro, Aya; Teixeira-Carvalho, Andréa; Martins‐Filho, Olindo Assis; Malheiro, Adriana

doi:10.1016/j.humimm.2014.08.198

Cited by 22 publications

(31 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mikadze and Vashakidze [54] reported a significant rise of IL-10 concentration in cases of severe hepatic lesions. Similarly, in our hands levels of TNF-α were higher amongst the HCV-NAI and HCV-AI than in the NI-AI patients and this agreed with reported higher levels of the same cytokine among HCV-infected patients compared to healthy controls [15,16].…”

Section: Discussionsupporting

confidence: 92%

“…Cytokines were frequently reported as markers for both HCV infection [15,16] and autoimmune diseases [17,18]. Contradictory results were published on levels of IL6 among HCV infected humans.…”

Section: Introductionmentioning

confidence: 99%

“…Contradictory results were published on levels of IL6 among HCV infected humans. While some demonstrated its decrease upon infection, [19] others showed its increase [15,16,20]. Interestingly, a study concluded IL6 as valuable markers for severity of HCV infection as its serum levels were higher among patients presenting severe infection compared to milder ones and also patients with genotype 1 showed higher serum levels of IL-6 than those with genotype 2 [21].…”

Section: Introductionmentioning

confidence: 99%

“…A study on Egyptian patients' demonstrated higher serum IL10 and TNF-α levels compared to non-infected control [15,16,22]. B cell activating factor (BAFF) is essential in B lymphocytes development, maturation and activation [23].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Maghraby¹,

Kamel²,

Fayed³

et al. 2019

Russ Open Med J

View full text Add to dashboard Cite

Introduction -Egypt has the highest prevalence of hepatitis C virus (HCV) infection which is reported to be associated with autoimmune manifestations. Aim -There is a need for markers that enable differentiation between viral and non-infected-autoimmune patients. Material and Methods -Levels of the B-cell activation factor (BAFF), IL6, IL10 and TNF-α were quantified by ELISA in sera from HCVinfected-autoimmune patients (HCV-AI), HCV-infected patients with no autoimmune diseases (HCV-NAI), non-infected autoimmune patients (NIAI) and healthy control humans (C). Results -HCV-infected patients were 12.96, 8.33, 69.44 and 36.11% positive for the auto-antibodies ANA, AMA, ASMA and AGPCA respectively. The BAFF level was significantly (P<0.05) higher among the NI-AI patients compared to the HCV-NAI, HCV-AI patients and healthy control humans (C). For the IL6, no significant differences were seen between various patients' groups. In case of the IL10, its , levels were significantly higher (P<0.05) in the HCV-AI, NI-AI and HCV-NAI patients in comparison to the C humans. Levels of TNF-α were significantly (P<0.001 and 0.0001) higher amongst the HCV-NAI and HCV-AI than in the NI-AI patients respectively. Also, levels of the TNF-α were significantly (P<0.0001) higher amongst the C compared to the NI-AI. Levels of TNF-α were not significant amongst the HCV-NAI and HCV-AI patients than in C subjects. Conclusion -The obtained results showed that both IL6 and BAFF can serve as markers for autoimmunity and/or autoimmunity resulting from severe HCV infection, whereas, IL10 and TNF-α can be considered as markers for HCV infection in Egypt (genotype is mostly 4a).

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Maghraby¹,

Kamel²,

Fayed³

et al. 2019

Russ Open Med J

View full text Add to dashboard Cite

show abstract

“…Eventually, serum level of IL-6 was increased significantly during treatment, then after the end of the treatment, the level of IL-6 was decreased significantly as shown in Table 5. These came in line with Villani [38] and Tarragô [39] who stated that IL-6 level was increased at the beginning of the treatment then decline to reach the level less than that of the pre-treatment. This was explained as, the eradication of virus by Sofosbuvir treatment regimens lead to restoration of immune response.…”

Section: Discussionsupporting

confidence: 83%

Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4

Saafan

Abobaker

Abbas

et al. 2020

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: In Egypt, 15% of the populations are suffering from chronic hepatitis C especially genotype 4. Sofosbuvir was approved by FDA in December 2013 for treatment of HCV genotypes 2 and 3 in combination with Ribavirin, and for genotypes 1 and 4 in combination with Peg-IFN. Recently, polymorphism of different genes and plasma levels of IL-6 were utilized for better prediction of HCV clearance. This study aimed at early prediction of the efficacy of HCV treatment with Sofosbuvir (Sovaldi) and comparing the antiviral efficacy of dual and triple Sovaldi combination therapy. Methodology: Blood samples were collected from 100 HCV positive patients and detected by real time PCR at three time intervals. SNP genotyping of INFL-4 gene was estimated by using real-time PCR with predesigned primers and Taqman probes. IL-6 serum level was estimated before, during and after the end of the treatment using ELISA assay based on human IL-6 KIT. Results: SNP genotyping of INFL-4 gene showed that 13.1% of patients carried ∆G/∆G, 30.4% patients had TT/TT and 56.5% patients possessed heterozygote allele ∆G/TT. Clinical data displayed that 13 patients were got relapsed at SVR 12. Serum level of IL-6 was noticed higher in HCV patients than healthy ones. Noteworthy, it was increased during treatment then decreased to a minimal level than begining of treatment. Conclusion: SNP in INFL-4 gene has displayed no effect in response to Sofosbuvir. Dual therapy had the same effect like triple therapy, so interferon could be withdrawn from the treatment regimen.

show abstract

Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P‐gp and OATP1B1/BCRP on Patients With Different Stages of Hepatic Fibrosis

Pippa

Vieira

Caris

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The activity of the membrane transporters organic anion-transporting polypeptide 1B1 (OATP1B1) & breast cancer resistance protein (BCRP) (rosuvastatin) and P-glycoprotein (P-gp) (fexofenadine) was evaluated in patients with chronic hepatitis C virus (HCV) infection (n = 28), genotypes 1 and 3, investigated before the treatment with directacting antiviral agents (Phase 1) and up to 30 days after the assessment of the virologic response (Phase 2). Participants allocated in Groups 1 (n = 15; F0/F1 and F2, mild to moderate liver fibrosis) and 2 (n = 13; F3 and F4, advanced course of liver fibrosis/cirrhosis) received in both phases fexofenadine (10 mg) and rosuvastatin (2 mg). OATP1B1 & BCRP activity (rosuvastatin area under the plasma concentration-time curve of rosuvastatin from time zero to infinity (AUC 0-∞ )) was reduced in Groups 1 and 2, respectively, by 25% (ratio 0.75 (0.53-0.82), P < 0.01) and 31% (ratio 0.69 (0.46-0.85), P < 0.05) in Phase 1 compared with Phase 2. OATP1B1 & BCRP activity was reduced in Phases 1 and 2, respectively, by 49% (median ratio 1.51 (1.17-2.20), P < 0.05) and 61% (ratio 1.39 (1.16-2.02), P < 0.01) in Group 2 compared with Group 1. P-gp activity (fexofenadine AUC 0-∞ ) was also reduced in Phase 1 compared with Phase 2 (ratio Phase2/Phase1 0.79 (0.66-0.96) in Group 1 and 0.81 (0.69-0.96) in Group 2) as well as in Group 2 compared with Group 1 in both Phases (ratio Group2/Group1 1.47 (1.08-2.01) in Phase 1 and 1.51 (1.10-2.07) in Phase 2). Thus, clinicians administering OATP1B1 & BCRP and P-gp substrates with low therapeutic indexes should consider the evolution of the treatment and the stage of HCV infection.

show abstract

Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-α polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients

Cited by 22 publications

References 37 publications

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4

Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P‐gp and OATP1B1/BCRP on Patients With Different Stages of Hepatic Fibrosis

Contact Info

Product

Resources

About